Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Gallbladder cancer

3

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Fatty acid desaturase 2

3

Sphingolipid delta(4)-desaturase DES1

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1950

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Diagnostic

3

Inactive ingredient

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Playfair, L.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ECHA (EC/EINECS)

3

EPA CompTox

3

FDA UNII

3

JECFA EVALUATION

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MYRISTIC ACID

0I3V7S25AW

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1950

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingolipid delta(4)-desaturase DES1

Fatty acid desaturase 2

Conditions:

Gallbladder cancer

Ammonium myristate is passage-delaying substance. It was used as a substance for influencing gastrointestinal passage. The addition of ammonium myristate caused a delay of about 1.5 h in the transit time of the absorbing part of the gastrointestinal ...

tract. The addition of ammonium myristate improves the availability of nitrofurantoin from a slow releasing dosage form - an average increase is 23.8% of the total amount of nitrofurantoin excreted in the urine compared to the values obtained from the reference dosage form without the additional substance. The kinetics of renal elimination of nitrofurantoin is characterized by the longer duration of urinary excretion.

AMMONIUM MYRISTATE

6FX8H1ODBK

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1950

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingolipid delta(4)-desaturase DES1

Fatty acid desaturase 2

Conditions:

Gallbladder cancer

Ammonium myristate is passage-delaying substance. It was used as a substance for influencing gastrointestinal passage. The addition of ammonium myristate caused a delay of about 1.5 h in the transit time of the absorbing part of the gastrointestinal ...

tract. The addition of ammonium myristate improves the availability of nitrofurantoin from a slow releasing dosage form - an average increase is 23.8% of the total amount of nitrofurantoin excreted in the urine compared to the values obtained from the reference dosage form without the additional substance. The kinetics of renal elimination of nitrofurantoin is characterized by the longer duration of urinary excretion.

SODIUM MYRISTATE

06BLC4V0IV

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1950

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingolipid delta(4)-desaturase DES1

Fatty acid desaturase 2

Conditions:

Gallbladder cancer

Ammonium myristate is passage-delaying substance. It was used as a substance for influencing gastrointestinal passage. The addition of ammonium myristate caused a delay of about 1.5 h in the transit time of the absorbing part of the gastrointestinal ...

tract. The addition of ammonium myristate improves the availability of nitrofurantoin from a slow releasing dosage form - an average increase is 23.8% of the total amount of nitrofurantoin excreted in the urine compared to the values obtained from the reference dosage form without the additional substance. The kinetics of renal elimination of nitrofurantoin is characterized by the longer duration of urinary excretion.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1